X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES AJANTA PHARMA SUVEN LIFESCIENCES/
AJANTA PHARMA
 
P/E (TTM) x 20.8 21.0 99.0% View Chart
P/BV x 4.1 4.0 102.1% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 SUVEN LIFESCIENCES   AJANTA PHARMA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-18
AJANTA PHARMA
Mar-18
SUVEN LIFESCIENCES/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs2511,818 13.8%   
Low Rs1551,106 14.0%   
Sales per share (Unadj.) Rs49.1239.5 20.5%  
Earnings per share (Unadj.) Rs9.752.8 18.4%  
Cash flow per share (Unadj.) Rs11.459.5 19.1%  
Dividends per share (Unadj.) Rs1.500-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs60.3230.0 26.2%  
Shares outstanding (eoy) m127.2888.77 143.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.16.1 67.7%   
Avg P/E ratio x20.927.7 75.4%  
P/CF ratio (eoy) x17.824.6 72.5%  
Price / Book Value ratio x3.46.4 52.9%  
Dividend payout %15.40-   
Avg Mkt Cap Rs m25,825129,782 19.9%   
No. of employees `0001.16.8 15.8%   
Total wages/salary Rs m6133,765 16.3%   
Avg. sales/employee Rs Th5,832.63,128.4 186.4%   
Avg. wages/employee Rs Th571.5554.0 103.2%   
Avg. net profit/employee Rs Th1,153.8689.7 167.3%   
INCOME DATA
Net Sales Rs m6,25321,258 29.4%  
Other income Rs m233242 96.3%   
Total revenues Rs m6,48521,499 30.2%   
Gross profit Rs m1,9826,584 30.1%  
Depreciation Rs m213596 35.8%   
Interest Rs m464 1,129.3%   
Profit before tax Rs m1,9556,226 31.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7181,539 46.7%   
Profit after tax Rs m1,2374,686 26.4%  
Gross profit margin %31.731.0 102.3%  
Effective tax rate %36.724.7 148.6%   
Net profit margin %19.822.0 89.7%  
BALANCE SHEET DATA
Current assets Rs m5,62212,236 45.9%   
Current liabilities Rs m1,1683,461 33.7%   
Net working cap to sales %71.241.3 172.6%  
Current ratio x4.83.5 136.2%  
Inventory Days Days8160 135.2%  
Debtors Days Days3684 42.5%  
Net fixed assets Rs m3,32511,140 29.8%   
Share capital Rs m127177 72.0%   
"Free" reserves Rs m7,54720,237 37.3%   
Net worth Rs m7,67420,414 37.6%   
Long term debt Rs m1410 137.6%   
Total assets Rs m9,13524,486 37.3%  
Interest coverage x43.21,519.4 2.8%   
Debt to equity ratio x00 366.1%  
Sales to assets ratio x0.70.9 78.8%   
Return on assets %14.019.2 73.3%  
Return on equity %16.123.0 70.2%  
Return on capital %26.030.5 85.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,06611,667 43.4%   
Fx outflow Rs m2,0011,616 123.9%   
Net fx Rs m3,06510,052 30.5%   
CASH FLOW
From Operations Rs m6992,854 24.5%  
From Investments Rs m-6-2,604 0.2%  
From Financial Activity Rs m-577-2 28,850.0%  
Net Cashflow Rs m116248 46.9%  

Share Holding

Indian Promoters % 63.4 73.8 85.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 1.6 -  
FIIs % 0.0 7.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 17.0 214.7%  
Shareholders   37,287 20,968 177.8%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   VENUS REMEDIES  ORCHID PHARMA LTD  PFIZER  TTK HEALTHCARE  SHASUN PHARMA  

Compare SUVEN LIFESCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 66 Points Higher; Realty and Consumer Durable Stocks Witness Buying(Closing)

Indian share markets continued to witness volatility during closing hours and ended their day on a flat note.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

SUVEN LIFE Announces Quarterly Results (2QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, SUVEN LIFE has posted a net profit of Rs 180 m (down 43.3% YoY). Sales on the other hand came in at Rs 895 m (down 16.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Jun 19, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 5-YR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS